For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 19,819 | 16,024* | 20,860 | 15,187 |
| General and administrative | 4,485 | 3,932* | 3,557 | 3,965 |
| Total operating expenses | 24,304 | 19,956 | 24,417 | 19,152 |
| Operating loss | -24,304 | -19,956* | -24,417 | -19,152 |
| Interest and investment income, net | 1,402 | 1,872* | 1,125 | 1,314 |
| Interest expense | - | 0* | 0 | 0 |
| Other (expense) income, net | -67 | 1,054* | -50 | 176 |
| Total other income, net | 1,335 | 2,926* | 1,075 | 1,490 |
| Net loss | -22,969 | -17,031 | -23,342 | -17,662 |
| Basic EPS | -1.23 | -1.106 | -1.9 | -1.44 |
| Diluted EPS | -1.23 | -1.106 | -1.9 | -1.44 |
| Basic Average Shares | 18,706,622 | 15,403,607 | 12,307,298 | 12,240,443 |
| Diluted Average Shares | 18,706,622 | 15,403,607 | 12,307,298 | 12,240,443 |
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)